Jenny P. Glusker, PhD, DSc, Fox Chase professor emerita, has been awarded the William Procter Prize for Scientific Achievement by Sigma Xi, The Scientific Research Society. The annual award recognizes researchers who have made outstanding scientific contributions and have communicated their significance across disciplines. Glusker’s research interests include cancer-causing chemicals, enzyme mechanisms, and crystallography.
Fox Chase senior scientist Alfred G. Knudson Jr., MD, PhD, was honored as an Oncology Luminary by the American Society of Clinical Oncology during its 50th anniversary celebration. The honor recognizes exceptional individuals who have helped shape the field of oncology and have advanced progress against cancer. Knudson’s “two-hit” theory of cancer causation provided a unifying model for understanding cancer susceptibility in people with and without an inherited predisposition. Knudson also predicted the discovery of tumor suppressor genes.
Hilton Klein, DVM, director of the Laboratory Animal Health Facility, has received the American Association for Laboratory Animal Science’s 2014 Joseph J. Garvey Management Award. The award recognizes an AALAS member for outstanding administration, management, or support of programs relating to the care, quality, or humane treatment of animals used in biomedical research. The work of Garvey Award recipients benefits both the scientific workplace and the care of animals, and they demonstrate active involvement in AALAS on a volunteer basis.
Fox Chase has been recognized as a Center of Excellence by the Myelodysplastic Syndromes Foundation, one of four such centers in Pennsylvania. This designation honors institutions with an established research and academic program in myelodysplastic syndromes (MDS); recognized expertise; the ability to conduct and make available genetic research; a history of publications on MDS; and ongoing research into the syndrome, including Institutional Review Board-approved clinical trials. “As an MDS Center of Excellence, we offer patients with MDS state-of-the-art care,” says medical oncologist Patricia Kropf, MD, director of the Fox Chase-Temple MDS program. “We have clinical trials designed specifically for patients … Continue Reading »
Patients with HPV-Positive Throat Cancers More Likely to Make Complete Recovery without Surgery At the ASTRO 2014 Annual Meeting, Fox Chase radiation oncologist Thomas Galloway, MD, presented a study showing that patients with human papillomavirus (HPV)–positive oropharyngeal cancer see significantly higher rates of complete response on a post-radiation neck dissection than those without HPV. After radiation and chemotherapy, many head and neck cancer patients still have persistent lumps in their neck, albeit often smaller than when they were first diagnosed. Because surgery to remove these lumps can cause neck and shoulder problems and difficulty swallowing, Galloway’s team wanted to see if … Continue Reading »
Fisher Presents on Diffuse Large B Cell Lymphoma Variant Presenting at the 2014 Pan-Pacific Lymphoma Conference in Kohala, Hawaii, Fox Chase President and CEO Richard I. Fisher, MD, reviewed the biology, prognosis, and future therapies for double/triple hit, C-MYC alone diffuse large B cell lymphoma, a very aggressive variant that has poor response to standard therapy and poor overall survival. As more clinical research homes in on this disease, Fisher says, “the most provocative question is whether molecular abnormalities in these patients can be successfully targeted with new oral inhibitors.”
Clinical Faculty Research Faculty
TOPLINE Researchers identified transporter membrane protein ABCC10 as a viable target in mammary tumors; next, they will test its potential as a target in lung tumors A collaborative search for an optimized ABCC10 inhibitor is underway using molecular models Because of their ability to carry drugs out of cells, affecting biological processes such as metastasis, migration, and proliferation, transporter membrane proteins have long been a focus in cancer research. For the last 30 years, much of the research in this area has focused on P-glycoprotein, or Pgp, but after many failed studies and clinical trials, research on Pgp has fallen out … Continue Reading »
THE TOPLINE Early results from a Phase I trial indicate that the antibody-drug conjugate IMMU-130 is safe and tolerable in treating relapsed metastatic colorectal cancers Investigators believe IMMU-130 may be more potent than the traditional treatment, as it binds directly to cancer cells Fox Chase medical oncologist Efrat Dotan, MD, is spearheading a Phase I clinical trial of IMMU-130, an antibody-drug conjugate, studying its efficacy and safety for use against metastatic colorectal cancers (mCRC) that have relapsed. “This is a novel treatment approach using an antibody-drug conjugate to deliver the treatment directly into the cancer cell and limit toxicity to healthy … Continue Reading »